Nevro1 has been proven to immediately transfix the sacroiliac joint for long-term fusion, according to a news release. It has self-contained deployable titanium anchors and 3D-printed technology to support bone growth and fusion.
The device will be the company’s flagship SI joint fusion product, Nevro CEO Kevin Thornal said in the release.
This is the first clearance since Nevro acquired Vyrsa Technologies and its portfolio of sacroiliac joint products.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
